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Abstract Although there are several data suggesting a link between lower lipids levels
and the risk of suicide, there are few data concerning lower lipids levels in patients with
dissociative disorders (DD). This is the first longitudinal study investigating the evolution
of the lipids levels during a specific 8 weeks of psychodynamic psychotherapy (PP) for
patients with DD. 32 patients diagnosed with DD (SCID for DSMIVR) were assessed with
Dissociative Experiences Scale (DES), Clinical Global Impression and Improvement Scale
and their lipids levels (total cholesterol, triglycerides, high-density lipoprotein, low-density
lipoprotein and very low density lipoprotein) were measured at inclusion and after 3 and
8 weeks of PP. 30 patients finished the study. There is a significant positive (p \ 0.05) link
between lower lipids levels (total cholesterol, LDL, triglycerids) and a higher level of
dissociation (DES scores) at the beginning and at the end of the study. Interestingly, we
found a significant (p = 0.018) positive link between the reduction of the dissociation
(DES) and the increase of the triglycerides levels after 8 weeks of treatment. While lower
lipids seems related to a higher level of dissociation before and after the treatment, an
increasing triglycerides level was observed after 8 weeks of PP in patients with a better
outcome. Further studies are needed with larger samples and control groups, in order to
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confirm these preliminary data. These findings could open the way for hypothesis about the
role of lipids in the pathophysiology of DD and raise the question of the patients with DD
receiving antilipidemiants agents.
Keywords Dissociative disorders  Psychodynamic psychotherapy  Lipids 
Triglycerides
Introduction
Different data suggest the existence of a link between lower lipids levels and several
neuropsychiatric disorders [1]. In particular, lowered lipids levels were reported to be
related to high rates of early death, suicide [2, 3], depression [4], anxiety [5], aggressive
and violent behaviors [6]. The authors suggest that serotonin plays a key role in under-
standing the underlying neurobiological mechanisms of the relationship between low lipids
levels and major depression, suicide and violence.
Among the possible mediators of suicidal behavior dissociation has been widely
reported especially in sexually abused children and adolescents. Besides suicidality, dis-
sociative disorders (DD) have been related also to risk-taking behaviors, such as self-
mutilation, physical and sexual aggression, substance abuse, and sexual revictimization [7].
In spite of an abundant literature about links between major depression with suicidal
ideas and lower lipids levels [4], there are few data suggesting lower lipids levels in
patients with DD [8]. However, a better understanding of the possible links between lipids
levels and DD could open the question of the underlying neurobiological mechanisms of
the suicidal attempts and depressive symptoms in patients with DD. Moreover, the question
of possible side effects of antilipidemiants agents could be raised.
The aim of this study is to investigate the evolution of the lipids levels during a specific
program of 8 weeks of psychodynamic psychotherapy (PP) treatment for patients with DD.
The interest of this study resides in the observation of the dynamic relation between the
level of dissociation during a psychotherapeutic specific treatment and the lipids levels.
Methods
Patients
Patients aged 18–65 years were interviewed according to the Dissociative Experiences
Scale (DES), [9]. If their dissociation score was equal or higher than 30, the Structured
Clinical Interview for DSM-IV Dissociative Disorders (SCID) [10, 11] was administered.
Therefore, after a careful screening of 238 patients admitted at the emergency room of the
University Hospital of Geneva or in emergency at a general practitioner private center, 32
patients were selected for the study.
The exclusion criteria were: presence of a major medical illness, as documented by the
medical history and physical examination, pregnancy or lactation, suicidal ideation or
behavior, substance dependence, dyslipidemia, or participation in another drug trial within
4 weeks prior enrolment into this study.
The study was approved by the local Ethical committee and by the SwissMedic and was
registered before of the beginning of the study in Clinical Trials gov.com. After a careful
explanation of the study, all patients provided their informed written consent to participate.
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Measures
The patients were assessed before (T1) and after three (T2) and eight (T3) weeks of
treatment. The assessments and measures included the DES, the Clinical Global Impres-
sion and Improvement Scale (CGI-I), Hamilton Depression Rating Scale (HDRS), the
Montgomery and Asberg Depression Rating Scale items for suicide (MADRS) and the
Helping Alliance Questionnaire of Luborsky [12]. The total cholesterol, triglyceride, high-
density lipoprotein, low-density lipoprotein, and very low density lipoprotein levels were
evaluated in the morning between 8 and 9 AM in all subjects after an overnight fasting
period.
Efficacy Variables
A favorable outcome was defined as either a complete remission of symptoms after
8 weeks of treatment, or a DES-score of\25, or a reduction of at least 20 % on the DES
scores. A favorable outcome was also considered if there was a reduction at least 30 % at
of the total CGI-I scores. Partial remission was considered as a reduction of at least 15 %
of the total CGI-I scores.
Treatment
The patients were treated by a psychiatrist (CD) who has experience with the use of the
specific combined treatment for DD. The psychotherapeutic follow-up is fully described
elsewhere [13]. According to our specific psychotherapeutic model, after the immediate
resolution of the initial crisis or emergency generated by the acute dissociation, we tem-
porarily prolonged the crisis situation, so that the patient and his family could re-negotiate the
conflict precipitating ‘‘the crisis’’. During the first phase of the psychotherapy, the medical
team discusses the demand of help and encourages the patient and his family to take into
account the conflicts revealed by the ‘‘crisis’’ leading to acute dissociation. In a second phase,
we investigate the subjective experience of the patient, exploring his interpersonal and
intrapsychic conflicts. Then, in a third phase, the specific aim of our interventions focus the
traumatizing experiences (real or imaginary) from the past and discover bad copping strat-
egies in the present, following a frequently unconscious ‘‘repetition scenario’’. The psy-
chotherapy open to the patients the opportunity to analyze and discover new events of their
life, without a rigid reference to the past traumatizing experiences. This new experience
discovered during the psychotherapeutic process, lead to less dissociation, which remain a
bad copping strategy in order to avoid some real or imaginary traumatizing experiences.
Another independent psychiatrist (CL) assessed the patients following a methodology
described in previously [14].
The combined treatment included PP (1 h session each week) and antidepressants or
antipsychotics, when needed. In order to have homogeneity, our local guidelines recom-
mend quetiapine (400 mg/day) as an antipsychotic and escitalopram (10 mg/day) as an
antidepressant for naı¨ve drug patients.
Statistical Analyses
The difference in clinical and biological parameters at the different assessment times was
assessed by ANOVA analysis for repeated measures. The possible relationship between
clinical and biological parameters was measured by the Pearson’s analysis.
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This is a first pilot study and we didn’t have to determine the sample size. Nevertheless
we considered that 30 patients are needed to detect, at the 5 % significance level with 80 %
power, a 30 % success difference between any follow-up (CGI-I variation) assessments.
Those indicative data were considered following similar studies concerning the efficacy of
the psychotherapeutic treatment in patients with DD [15].
Results
The study was ended with 32 patients (30 completers, one patient with dropout and one
patient diagnosed with hyperlipidemia requiring treatment). The patients with DD pre-
sented amnesia and depersonalization. The mean age of the patients was 38.15 with a
standard deviation at 9.8. The man/woman ratio was 1.9.
No patients requiring an antidepressant (escitalopram) or an antipsychotic treatment
(quetiapine) were included in the study, because of their concomitant suicidal ideas, or
substance dependences, which were exclusion criteria. This means that included patients
benefited only of psychodynamic psychotherapy.
Specific psychotherapeutic treatment was effective for improving of dissociation,
because 83 % of patients meet the criteria of success and diminish their dissociation levels
with at least 20 % reduction on the DES, or 30 % reduction on the CGI-I. No significant
side effect was observed during the study and no patient required hospitalization during the
study.
The evolution of the lipids levels expressed in mmol/l (total cholesterol, LDL, tri-
glycerides, HDL) during the study (intake, after 3 and 8 weeks of treatment) is showed in
the Fig. 1.
We observed a significant reduction in the DES Scores during the treatment and we
showed this evolution of the DES scores (Baseline, after 3 and 8 weeks of treatment) in the
Table 1.
We find a significant positive link (p \ 0.05) detected between lower lipids levels (only
in total cholesterol, LDL and triglycerides) and a higher level of dissociation (DES scores),
as shown by the DES total scores, at the beginning and after 3 and 8 weeks of treatment.
We did not find significant relation between the levels of HDL and the level of
dissociation.
Interestingly, the reduction of the dissociation (DES) was significantly positively
(p = 0.018) related only to the increase of the triglycerides levels at the time T2, after
8 weeks of treatment.
There was no significant relation between the age, the sex, other demographic or clinical
features and the type of DD (amnesia or depersonalization) and the levels of dissociation or
the response to the treatment. There were no other comorbid disorders in included patients.
Discussion
Taking into account the relation existing between DD and depression or suicide and several
data suggesting a link between lower lipids levels in patients with depression and suicide
[2–4], we proposed a first pilot study monitoring the lipids levels during 8 weeks of
specific psychotherapy in patients with DD.
Our findings are concordant with previous data suggesting that lower lipids levels are
linked to a higher level of dissociation [8]. This concordance could be related to the similar
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levels of dissociation in our sample and in the patients with DD studied by Agargun et al.
[8].
Interestingly, our data suggests that a higher increase in the triglyceride levels could be
related to a better outcome in patients with DD, measured by a significant diminution of the
DES scores. If larger studies, including control groups, should confirm those preliminary
data, the lipids profile could be a predictor of the evolution in patients with DD. This
hypothesis is concordant with similar data suggesting that a low docosahexaenoic acid
percentage and low omega-3 proportions of lipid profile could predict the risk of suicidal
behavior among depressed patients over a 2-year period [3].
Moreover this finding, if confirmed, could open new hypothesis about the neurobiology
of dissociation in patients with DD, but also in patients with suicidal ideas, major
depression and dissociation. The question of the dissociation and depression in patients
receiving antilipidemiants could also be raised.
The principal limitation of this study are the little sample size (n = 30) and the lack of
the control group. However, the link between lower lipids levels in patients with DD versus
normal control was already described [8]. Thus, the interest of this pilot study was to
search for the first time the evolution of the lipids levels during the treatment, by
Fig. 1 The evolution of the lipids levels (mmol/l) during treatment: baseline, after 3 and 8 weeks of
treatment. Those data are including all 30 completer subjects and not only the subjects who improved with
the treatment
Table 1 The evolution of the
DES Scores: baseline versus 3
and 8 weeks of evolution
DES score Standard deviation
DES baseline 47.57 6.7
DES after 3 weeks of treatment 33.63 9.0
DES after 8 weeks of treatment 23.73 15.6
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comparing the patients to themselves (longitudinal study), rather than a transversal study
with a control group [8].
In spite of recent efforts of the International Society for the Study of Dissociative
Disorders (ISSD), the treatment of the DD remains controversial. The combined treatment
seems to be the best approach: psychotherapy and pharmacotherapy, adapted for the
comorbidities (depressive, anxious, psychotic symptoms). In our sample we didn’t include
patients requiring additionally pharmacological agents, because those patients had also
suicidal ideas, or substance dependence, which were exclusion criteria. This is a supple-
mentary limitation for our study, because many patients with DD require pharmacotherapy
for their frequent comorbidities. Nevertheless, this could also be considered strength for
this study, because the increasing lipids levels observed have not an exogenous explication,
linked to medication (especially to the antipsychotics).
The very good response to the PP (83 % of the patients reduce at least 30 % of their
CGI-I scores during the 8 weeks study period) is concordant with previous observation of
patients who not require pharmacological agents and without suicidal ideas and substance
dependence [15]. The very good response to the psychotherapy (the important decrease of
DES scores) could explain the significant increase of triglycerides observed, in spite of the
small sample size (n = 30).
We could also imagine that the increase of triglycerides could be partially linked to
subtle changes in the alimentation of some patients who testifies an increasing hedonia
linked to their meals. Nevertheless, this preliminary study did not measure specifically the
changes in the alimentation of the patients during the study.
The fact that we include only 32 patients among 238 patients is concordant with the
literature suggesting the prevalence of patients with DD among outpatients consulting in
emergency [16].
Several studies should clarify the neurobiological link existing between triglycerides
and lipids in general and suicide, dissociation and depression. Serotonin seems to play a
key role in this mediation [8], but we didn’t find any evidence about specific role of
triglycerides rather than other lipids.
Conclusion
In spite of several data suggesting a link between lower lipids levels and the risk of suicide
and major depression, there are few data concerning lower lipids levels in patients with
DD. This is the first longitudinal pilot study investigating the evolution of the lipids levels
during a specific 8 weeks of PP for patients with DD. Larger studies, including control
groups, should confirm those preliminary data, suggesting lower lipids levels related to
higher level of dissociation (DES scores) and higher triglycerides levels during the psy-
chotherapeutic treatment in patients with a better outcome. This could open new
hypothesis concerning the pathophysiology of DD and raised the question of patients
receiving antilipidemiants agents, especially if they present a DD.
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